FDA advisors unanimously vote to approve Moderna's mRNA after agency drama
In February, a Trump official refused to review the vaccine.
Signal weather
Rising
Momentum is building quickly, so this card is a good early entry point into the topic.
Independent advisors for the Food and Drug Administration on Friday voted 9–0 in support of approving Moderna's seasonal mRNA flu vaccine, which a Trump appointee at the agency initially tried to block from even being reviewed. In an all-day meeting, members of the FDA's advisory committee—known as VRBPAC for Vaccines and Related Biological Products Advisory Committee—pored over data and presentations on the vaccine, which is dubbed mRNA-1010 and branded as mFlusiva. The presentations included a review from FDA scientists, which was supportive of the vaccine. Data from a Phase 3 trial including over 40,000 adults age 50 and older found the mRNA vaccine was around 27 percent more effective against seasonal flu than a standard flu shot. A smaller Phase 3 trial, involving data from nearly 3,000 people age 65 years and older, showed the shot produces stronger immune responses than a high-dose flu vaccine, which is recommended for this age group. The safety profile of the vaccine was also generally good. Read full article Comments
Stay on the signal
Follow FDA advisors unanimously vote to approve Moderna's mRNA after agency drama
Follow this story beyond a single article: new follow-ups, adjacent sources, and the evolving storyline.
Story map
Understand this topic fast
A quick entry into the story: why it matters now, who is involved, and where to go next for context.
Why it matters now
Topic constellation
Open the live map for this story
See which entities, story threads, sources, and follow-up articles shape this story right now.
Click nodes to continue
Entity pages
Story timeline
Continue with this story
A short sequence of events and follow-up stories to understand the arc quickly.
How reliable this looks
Signal and trust for Ars Technica
This source works at a rapid pace: 100% of recent stories land in the hot window, and 0% carry visible search signal.
Reliability
92
Freshness
100
Sources in storyline
1
Related articles
More stories that share tags, source, or category context.
The UK will scan asylum-seekers’ faces for age checks—despite knowing the tech is flawed
Tests of age-verification technology show the risks of life-altering errors.
Signal weather
Momentum is building quickly, so this card is a good early entry point into the topic.
Why now
Fresh coverage with immediate momentum.
Rocket Report: Rebuild begins at Blue Origin launch pad; Relativity targets Mars
A French launch startup is scrapping the name of its rocket, apparently due to a trademark issue.
Signal weather
Momentum is building quickly, so this card is a good early entry point into the topic.
Why now
Fresh coverage with immediate momentum.
As global warming threatens corals, scientists search for reefs that can take the heat
Researchers say these coral strongholds may help repopulate more degraded reefs.
Signal weather
Momentum is building quickly, so this card is a good early entry point into the topic.
Why now
Fresh coverage with immediate momentum.
A bold satellite rescue mission came together in record time, but will it work?
"I consider this a success already, just from the fact that we're even going to try this."
Signal weather
Momentum is building quickly, so this card is a good early entry point into the topic.
Why now
Fresh coverage with immediate momentum.
More from Ars Technica
Fresh reporting and follow-up coverage from the same newsroom.
The UK will scan asylum-seekers’ faces for age checks—despite knowing the tech is flawed
Tests of age-verification technology show the risks of life-altering errors.
Signal weather
Momentum is building quickly, so this card is a good early entry point into the topic.
Why now
Fresh coverage with immediate momentum.
Rocket Report: Rebuild begins at Blue Origin launch pad; Relativity targets Mars
A French launch startup is scrapping the name of its rocket, apparently due to a trademark issue.
Signal weather
Momentum is building quickly, so this card is a good early entry point into the topic.
Why now
Fresh coverage with immediate momentum.
As global warming threatens corals, scientists search for reefs that can take the heat
Researchers say these coral strongholds may help repopulate more degraded reefs.
Signal weather
Momentum is building quickly, so this card is a good early entry point into the topic.
Why now
Fresh coverage with immediate momentum.
A bold satellite rescue mission came together in record time, but will it work?
"I consider this a success already, just from the fact that we're even going to try this."
Signal weather
Momentum is building quickly, so this card is a good early entry point into the topic.
Why now
Fresh coverage with immediate momentum.